The approval of Denali’s Hunter syndrome treatment, Avlayah, comes after a series of drug rejections and delays that had led to criticism of the FDA’s stance on rare disease therapies.

Original title: “FDA clears Denali drug in ‘clear step’ for rare disease biotechs”

Wave’s drug, which is meant to improve body composition, disappointed investors but was defended by analysts. Elsewhere, Kodiak’s revived vision loss treatment succeeded in a second Phase 3 trial.

Original title: “Wave crashes on obesity drug update; Kodiak’s reboot pays dividends”

Avlayah is the first Hunter syndrome therapy approved to address the condition’s neurologic complications, according to Tracy Beth Høeg, acting director of the Center for Drug Evaluation and Research.

Original title: “Denali Delivers ‘Welcome Positive’ for Rare Disease Space With FDA's Hunter Syndrome Nod”

Compressed air is among the largest energy expenses in pharmaceutical manufacturing and must remain entirely contamination-free.

Original title: “Clean Air Advantage”

The U.S. Food and Drug Administration approved Avlayah (tividenofusp alfa-eknm) to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).

Original title: “FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome ”

Long-awaited results from Phase 1/2 studies lifted Sarepta’s stock and, according to the company, suggest potential for two medicines to treat muscle-weakening conditions.

Original title: “Sarepta sees early success with RNAi drugs from Arrowhead”

Missing one of its co-primary endpoints could make it difficult for Karyopharm Therapeutics to score conventional approval for Xpovio in myelofibrosis, according to Jefferies analysts.

Original title: “Karyopharm Slides as Mixed Myelofibrosis Results Cloud Regulatory Road”

While ersodetug missed the Phase 3 primary endpoint of a reduction in hypoglycemia events, Rezolute argued that this goal was confounded in part by behavioral factors. The FDA acknowledged the validity of this argument.

Original title: “Rezolute Lauds ‘Unusual’ FDA Feedback Supportive of Path Forward for Hypoglycemia Drug”

Company shares climbed by more than 20% on Phase 2 study results suggesting the therapy could provide sustained relief when administered once every three or six months.

Original title: “Apogee strengthens case for longer-lasting eczema drug”

The partners said the shot produced “clinically meaningful” efficacy despite missing its main study objective, a finding they blamed on a lower-than-expected rate of infections during the trial.

Original title: “Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results”

The multivalent candidate, being developed by Pfizer and French partner Valneva under a 2020 pact, generated higher than 73% efficacy against the tick-borne disease in a Phase 3 trial—but failed to hit a predetermined confidence interval.

Original title: “Pfizer ‘Confident’ in Valneva-Partnered Lyme Vaccine Despite Missed Primary Endpoint”

Ondine Biomedical has announced the North American phase 3 study has reached more than 93% enrolment, bringing the company closer to FDA submission.

Original title: “Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone”

This rare inherited eye disease causes progressive vision loss and eventual blindness, with no approved treatments currently available ... The Department of Health – Abu Dhabi has announced the launch and funding of a UAE-first clinical trial for a novel gene therapy for MerTK-related retinitis ... This rare inherited eye disease causes progressive vision loss and eventual blindness, with no approved treatments currently available ... The Department of Health – Abu Dhabi has announced the launch and funding of a UAE-first clinical trial for a novel gene therapy for MerTK-related retinitis pigmentosa (RP) developed by Opus Genetics. The initiative brings together Opus Genetics (a US-based clinical-stage biopharmaceutical company), the Innovative Research Oversight and Support (IROS) division of the M42 group, Cleveland Clinic Abu Dhabi to accelerate the development of novel gene therapies for Inherited Retinal Diseases, which affect approximately five percent of the population in this region. Cleveland Clinic Abu Dhabi will serve as the clinical site, while IROS will oversee the trial design, patient recruitment and clinical operations. Clinical development activities are expected to commence in 2026, marking a milestone for rare disease treatment in Abu Dhabi and the region. This rare inherited eye disease causes progressive vision loss and eventual blindness, with no approved treatments currently available. This groundbreaking initiative reflects Abu Dhabi’s commitment to advancing innovative solutions for rare conditions and reinforces the Emirate’s position as a global hub for life sciences and biomedical innovation. The first-of-its-kind clinical trial is the result of a collaborative effort between the Department of Health – Abu Dhabi and the Authority of Social Contribution - Ma'an, reflecting their shared commitment to advancing healthcare research and innovation in Abu Dhabi. George Magrath, M.D., Chief Executive Officer of Opus Genetics, said, “For patients living with MerTK-related retinitis pigmentosa, this trial represents the first real opportunity to change the course of a disease that has historically led to inevitable vision loss.” · Dr. Fahed Almarzooqi, Chief Executive Officer of M42's Integrated Health Solutions, stated, “This trial represents a pivotal step in strengthening Abu Dhabi’s position as a global hub for biotech innovation. Through strategic partnerships and clinical excellence, we are translating scientific breakthroughs into real-world treatments for patients with urgent, unmet needs.”

Original title: “Abu Dhabi launches UAE’s first gene therapy clinical trial”

In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not consistently” improving muscle growth and motor function in a key study.

Original title: “Roche stops work on experimental SMA drug”

At its peak, Imcivree’s sales in hypothalamic obesity could reach over $2 billion worldwide, according to analysts at Stifel.

Original title: “Rhythm Bounces Back from Phase 3 Fail with FDA Nod for Rare Obesity Injection”

Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to be worth more than $1 billion.

Original title: “Rhythm obesity drug wins broader use from FDA”

The clearance, issued 54 days after an approval submission, gives Novo another chance to claw back market share from Eli Lilly.

Original title: “Novo uses FDA voucher to win speedy approval of higher-dose Wegovy”

The U.S. Food and Drug Administration today approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection for weight loss and long-term maintenance of weight loss for certain adult patients.

Original title: “FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide”